JPH026738B2 - - Google Patents

Description

DETAILED DESCRIPTION OF THE INVENTION The present invention relates to therapeutic adhesive tapes or sheets.

A therapeutic adhesive tape or sheet, which has a thin layer of pressure-sensitive adhesive mixed with a therapeutic drug on the base material, is applied to the skin, and local therapy can be performed using the drug that oozes from the pressure-sensitive adhesive layer. , is attracting attention as a new treatment method to replace the conventional occlusive dressing therapy (ODT therapy).

As such therapeutic adhesive tapes or sheets, there are, for example, pressure-sensitive adhesives made of copolymers of acrylic esters and acrylic acids mixed with steroid hormones as drugs. However, such pressure-sensitive adhesives do not consist only of chemically inert acrylic acid ester components, but also contain chemically active acrylic acid as a copolymerized component, so they can be used with drugs. The chemically active groups react and deteriorate, which tends to impair the drug's efficacy. For this reason, the use of pressure-sensitive adhesives made only of acrylic ester polymers, which do not have chemically active groups, has been considered, but this method may prevent the pressure-sensitive adhesives from adhering to the skin (residual adhesive) when peeled off. In addition, there was a risk that sufficient internal cohesive force would not be obtained, and that acrylic acid ester that does not participate in polymerization may remain in the polymer, causing deterioration of the drug.

The present invention was made with the aim of solving the above-mentioned drawbacks, and the pressure-sensitive adhesive does not react with drugs and deteriorate in quality, and can be used against a wide range of drugs, such as highly polar and highly hydrophilic drugs. To provide a therapeutic adhesive tape or sheet that has high compatibility with the skin, has sufficient internal cohesive force to prevent adhesive from remaining on the skin when peeled off after application, and is not toxic or irritating to the skin. With the goal. The gist of the present invention is to provide a therapeutic adhesive tape or sheet in which a base material is provided with a pressure-sensitive adhesive layer containing a drug, in which the pressure-sensitive adhesive has a copolymerized content of diacetone acrylamide of 5 to 45 mol%. , consisting of a copolymer in which the copolymerization content of methacrylic acid alkyl ester is 0 to 60 mol%, and the copolymerization content of acrylic acid alkyl ester is 35 to 85 mol%, the total of diacetone acrylamide and methacrylic acid alkyl ester The ratio of the number of moles to the number of moles of the acrylic acid alkyl ester is within the range of 65:35 to 15:85, the number of carbon atoms in the alkyl group of the methacrylic acid alkyl ester is 1 to 12, and the alkyl group of the acrylic acid alkyl ester is A therapeutic adhesive tape or sheet having 4 to 12 carbon atoms.

Next, the therapeutic adhesive tape or sheet of the present invention will be explained in more detail.

The base material used in the present invention is preferably a flexible material such as polyethylene, ethylene-vinyl acetate copolymer, soft polyvinyl chloride, or cellophane, and the thickness of the base material is 0.02 to 0.15 mm. A range is preferred.

The base material is subjected to corona discharge treatment, plasma treatment, primer coating, etc., if necessary, in order to increase the adhesion with the pressure-sensitive adhesive layer.

The pressure-sensitive adhesive layer basically consists of a copolymer of diacetone acrylamide, alkyl methacrylate, and alkyl acrylate.

However, it is possible to reduce the amount of methacrylic acid alkyl ester used, and a copolymer of diacetone acrylamide and acrylic acid alkyl ester is also included in the present invention.

The reason why the pressure sensitive adhesive is made of a copolymer of each of the above components is as follows.

The homopolymer of acrylic acid alkyl ester is
The adhesive force that imparts adhesion to the adherend is extremely large, and the cohesive force required to prevent the pressure-sensitive adhesive from adhering to the adherend or slipping is insufficient. However, by using a copolymer of diacetone acrylamide and an acrylic acid alkyl ester, or a copolymer of diacetone acrylamide and a methacrylic acid alkyl ester and an acrylic acid alkyl ester, the adhesive strength and cohesive force of the therapeutic adhesive tape can be improved. Alternatively, it can be made into a good sheet. The improvement in cohesive force is thought to be due to the improvement in the intermolecular force between the molecular chains of the copolymer due to the high polarity, hydrogen bonding properties, etc. of diacetone acrylamide. A copolymer of methacrylic acid alkyl ester and acrylic acid alkyl ester may be used in terms of obtaining adhesive strength and cohesive force, but it is also possible to obtain compatibility with highly polar and highly hydrophilic drugs and improve the polymerization rate. Therefore, diacetone acrylamide is used as a copolymerization component.

The greatest advantage of using diacetone acrylamide as a copolymerization component is that it has excellent compatibility with drugs. Diacetone acrylamide has a diacetone group and an amide bond, making it highly polar and highly hydrophilic, so it has good compatibility with a wide range of drugs. In the case of copolymers of acid alkyl esters, excellent compatibility can be obtained even with highly polar and highly hydrophilic drugs, which tend to cause precipitation due to poor compatibility.

Furthermore, diacetone acrylamide has excellent copolymerizability with methacrylic acid alkyl esters and acrylic acid alkyl esters, can prevent runaway polymerization during polymerization, and has the function of improving the polymerization rate.

Furthermore, diacetone acrylamide has hydrophilic properties and the adhesive itself absorbs some moisture, so when used as a therapeutic adhesive tape or sheet, it absorbs sweat and also has the function of aiding the diffusion and movement of drugs. .

It has excellent adhesive strength as a therapeutic adhesive tape or sheet, does not cause pain when peeled off, and has excellent cohesive strength that prevents adhesive from extruding or slipping when it is adhered. Moreover, the copolymerization components, which have good compatibility with highly polar and highly hydrophilic drugs, are 5 to 45 mol% of diacetone acrylamide, 0 to 60 mol% of methacrylic acid alkyl ester, and 35 mol% of acrylic acid alkyl ester. ~85 mol%, and the ratio of the total number of moles of diacetone acrylamide and alkyl methacrylate to the number of moles of alkyl acrylate in the copolymer is in the range of 65:35 to 18:85. It has become clear through research by the present inventors that it is better to assume that

Methacrylic acid alkyl esters provide the cohesive strength of pressure-sensitive adhesives, and acrylic acid alkyl esters provide the adhesive strength of pressure-sensitive adhesives, but cohesive strength, adhesive strength, and drug compatibility are important for therapeutic adhesives. In order to make the tape or sheet optimal, the number of carbon atoms in the alkyl group of the alkyl methacrylate ester is 1 to 12, and the number of carbon atoms in the alkyl group of the alkyl acrylate ester is 4 to 12. Examples of methacrylic acid alkyl esters include methyl methacrylate, ethyl methacrylate, propyl methacrylate, isopropyl methacrylate, butyl methacrylate, isobutyl methacrylate, and methacrylate.
These include 2-ethylhexyl, n-octyl methacrylate, decyl methacrylate, isodecyl methacrylate, and lauryl methacrylate.

Examples of the acrylic acid alkyl ester include butyl acrylate, isobutyl acrylate, hexyl acrylate, 2-ethylbutyl acrylate, octyl acrylate, isooctyl acrylate, 2-ethylhexyl acrylate, decyl acrylate, isodecyl acrylate, lauryl acrylate, etc.

FIG. 1 illustrates the compositional range of three components: diacetone acrylamide, alkyl methacrylate, and alkyl acrylate. A
is diacetone acrylamide, B is a methacrylic acid alkyl ester, and C is an acrylic acid alkyl ester, and the vertices of A, B, and C indicate the positions where A, B, and C are respectively 100 mol%. The molar ratio of each component at point P is shown as follows: A:B:C=a:b:c.

In Figure 1, for example, from point P to the lower right, that is (C
As the amount of C component increases, the adhesive force increases, but the cohesive force becomes weaker and the drug compatibility also decreases. Also, by moving horizontally to the right or left from point P, the ratio of component A to the total does not change, but only the ratio of B to C changes. It can increase force and cohesive force. Since point P is in the direction of increasing the cohesive force as it moves away from point C (whether it approaches point A or point B), the number of carbon atoms in the alkyl group of component B is increased, for example, from 8 to 12. It is generally desirable to prevent loss of adhesion.

In other words, the required compatibility of individual drugs, adhesive strength,
The position of the P point and the number of carbon atoms in the alkyl groups of each component B and C are preferably determined from the balance of the three cohesive forces.

In the pressure-sensitive adhesive of the present invention, in addition to the above-mentioned components, for example, vinyl acetate, propionate, Examples include vinyl acetate, vinyl stearate, styrene, methacrylnitrile, dimethylacrylamide, vinyl chloride, ethylene, and butylene. Also, for example, 1,6-hexane glycol dimethacrylate,
By copolymerizing a difunctional polymerizable monomer such as polypropylene glycol dimethacrylate in a range of 0.001 to 0.02 mol% to generate slight crosslinking, it is possible to prevent stringiness and cracking of pressure-sensitive adhesives. .

In the production of pressure-sensitive adhesives, ordinary radical polymerization catalysts such as azobis compounds, peroxide compounds, and redox compounds are used to carry out solution polymerization, emulsion polymerization, suspension polymerization, radiation polymerization, etc. It is better to do it later, but for economical reasons,
High concentration solution polymerization is particularly suitable in terms of productivity, performance of the resulting polymer, etc.

Drugs include anti-inflammatory agents, anti-inflammatory analgesics, vasodilators, antihypertensive agents, antihypertensive diuretics, antiarrhythmia agents, tranquilizers, sedative-hypnotics, anti-temperature agents, anesthetics, anti-asthma drugs, antifungal agents, etc. A wide range of drugs can be used, and even when highly polar or highly hydrophilic drugs are used, they have excellent compatibility.

To obtain therapeutic adhesive tapes or sheets,
The drug is added as is or as a solution in a good solvent to the adhesive solution obtained by solution polymerization, and mixed thoroughly. An adhesive solution mixed with this agent is continuously applied onto silicone release paper so that the amount of pressure-sensitive adhesive after drying is a predetermined amount per unit area, then dried, and the product is applied to the adhesive surface. By pressing the base material, a product original fabric with a protected pressure-sensitive adhesive layer is obtained. This raw fabric is then cut into predetermined dimensions and packaged. To use, unwrap the product, remove the release paper, and apply it to an adherend such as the skin.

According to the therapeutic adhesive tape or sheet of the present invention, the pressure-sensitive adhesive does not react with drugs and cause deterioration of the drugs, and also has high compatibility with highly polar and highly hydrophilic drugs. It has excellent cohesive strength and does not leave adhesive residue on the skin when peeled off after application, has excellent adhesive properties when applied, and is not toxic or irritating to the skin.

Example 1 Diacetone acrylamide 11.8g (0.07mol) 2-ethylenehexyl methacrylate
45.5g (0.23 mol) Butyl acrylate 89.6g (0.70 mol) Ethyl acetate 37.0g The above solution was stirred at 65°C under a nitrogen gas atmosphere, and 0.5g of azobisisobutyronitrile was added.
was dissolved in 100 ml of ethyl acetate and added in 9 portions over 24 hours for polymerization. During this time, the viscosity increased excessively, so ethyl acetate was added as needed to continue copolymerization while maintaining a viscosity suitable for stirring.

After polymerization, a copolymer solution with a concentration of 25.1% by weight and a polymerization rate of 98.8% was obtained.

Add ethyl acetate to the above solution to make a concentration of 22.0% by weight, and 1.8 g of indomethacin per 100 g of the solution.
, 1 of methyl ethyl ketone versus methyl alcohol
The mixture was dissolved in a 1:1 mixture and adjusted to a concentration of 10% by weight, and then mixed.

The above solution was applied to a silicone release paper so that the weight after drying was 0.5 g ^per 100 cm2, and after drying, a 70 μm thick low density polyethylene film, one side of which had been subjected to a corona discharge treatment, was coated. The treated surface was crimped.

(Drug compatibility/re-release test) The sheet-like sample obtained as above was
No abnormal phenomena such as drug crystallization or precipitation were observed even after storage at room temperature (20°C, 60% RH) for 30 days, and even after storage at 60°C for 30 days under aging-promoting conditions.

Next, punch out this sheet into a circle with a diameter of 60 mm.
For each condition sample after 30 days at 20℃ and 30 days at 60℃, after removing the release paper, each sheet was immersed in 50ml of methyl alcohol for 3 hours at 30℃, and the amount of drug released in the methyl alcohol was measured. was measured by liquid chromatography, and the re-release rate relative to the original content was determined.

Sample after 30 days at 20℃ 90.6% Sample after 30 days at 60℃ 71.4% (Adhesion test) Cut the sample into a tape 15mm wide and 120mm long.
The adhesive surface was attached to a stainless steel plate for measuring adhesive strength, turned back 180 degrees from the end, peeled off at a speed of 300 mm/min, and the adhesive strength was measured (JIS-Z-1522 method).
did.

Sample after 30 days at 20°C: 486 g/15mm Sample after 30 days at 60°C: 459 g/15mm Even during adhesive force measurement, the adhesive did not cause any stringiness or cohesive failure phenomena.

Comparative Example 1 For comparison with Example 1, the following monomer composition solution, 2-ethylhexyl methacrylate
48.9 (0.247 mol) butyl acrylate 94.4 g (0.753 mol) ethyl acetate 36.0 g were polymerized using the same catalyst, method, and conditions as in Example 1 to obtain a solution with a concentration of 24.3% and a polymerization rate of 97.3%.
This solution was diluted to a concentration of 22.0%, 1.8 g of indomethacin was added per 100 g in the same manner, and a pressure-sensitive adhesive sheet was prepared in the same manner.

(Drug compatibility) When stored at 20℃ for 30 days, the drug tends to precipitate slightly (1
After 30 days at 60°C, numerous precipitates were observed over the entire surface, indicating very poor compatibility ^.

(Adhesive Strength) The adhesive strength was measured after 30 days at 20° C. in the same manner as in Example 1, and was found to be 480 to 910 g/15 mm.

However, the value rises in the latter half of the measurement due to a slight drag phenomenon of the adhesive, and cannot be said to be a normal value. This indicated that the cohesive force was insufficient, and that there was a risk that the adhesive would protrude, shift, or peel off during use.

Example 2 Diacetone acrylamide 57.5g (0.34mol) Butyl methacrylate 17.0g (0.12mol) 2-ethylhexyl acrylate
99.4g (0.54mol) Ethyl acetate 40g Methyl ethyl ketone 4g The above solution was heated at 60°C in an atmosphere purged with nitrogen gas.
While stirring at
ml solution, which was divided into 9 portions and added over a polymerization time of 28 hours. During this time, in response to the increase in viscosity, the concentration was gradually reduced by adding ethyl acetate in the same manner as in Example 1, to obtain a solution with a concentration of 27.7% by weight and a polymerization rate of 99.6%.

The above solution was diluted with ethyl acetate to a concentration of 24% by weight, and drugs (anti-inflammatory, analgesic) were added per 100 g of this solution.
4 g of methyl salicylate, 3 g of l-menthol, and 3 g of dl-camphor were mixed to obtain a drug-containing adhesive solution.

From this solution, the weight after drying is calculated per ^100cm2 .
70g, and a polyvinyl chloride resin film (thickness 90μ) that does not contain plasticizer as the base material.
A therapeutic sheet was prepared in the same manner as in Example 1 using 1).

The drug was completely dissolved in the adhesive and showed no tendency to ooze out. Also, cut this into 5cm x 5cm,
When applied to the skin (back side), it adhered well even after 24 hours without peeling off naturally, and the adhesive protruded to the surrounding area by less than 2 mm on all sides, indicating that it has high practical value. .

Adhesive strength was measured using the same method as Example 1.
After storage for 30 days at 20℃, the adhesive weight is 690g/15mm.
No particular abnormality was observed in the adhesive.

Comparative Example 2 For comparison with Example 2, the following monomer composition solution: Butyl methacrylate 25.8g (0.182 mol) 2-ethylhexyl acrylate
150.6 g (0.818 mol) and 44. g of ethyl acetate were polymerized using the same contact, method, and conditions as in Example 2 to obtain a solution with a concentration of 25.9% by weight and a polymerization rate of 97.9%.

Ethyl acetate was added to this solution to make it 24.0% by weight, and 4 g of methyl salicylate, 3 g of menthol, and 3 g of camphor were mixed per 100 g of this solution, and a therapeutic adhesive sheet was prepared in the same manner as in Example 2.

The adhesive feels sticky to the touch, and when applied to the skin, a 2mm to 4mm protrusion of the adhesive can be seen around the skin within 24 hours, and after it is removed, there is a significant amount of adhesive left on the skin. Admitted. In addition, when measuring the adhesive strength, a cohesive failure phenomenon of the adhesive was observed on the sample plate, and correct values could not be obtained.

Example 3 Diacetone acrylamide 25.4g (0.15mol) Lauroyl methacrylate 127.0g (0.50mol) 2-ethylhexyl acrylate
64.4g (0.35mol) Ethyl acetate 54.0g The above solution was replaced with nitrogen gas,
Stir at 67°C, make a solution of 0.97 g of benzoyl peroxide in 100 ml of ethyl acetate, and add it in 8 portions to polymerize over 26 hours. In the end, a solution with a concentration of 25.0% by weight and a polymerization rate of 99.2% was obtained. Ta.

The above solution was made 22.0% by weight with ethyl acetate, and diclofenac sodium was 1.5% per 100g of the solution.
g was added as a solution in methyl alcohol and mixed. Next, an ethylene/vinyl acetate copolymer resin film (thickness 70 μm, single side corona discharge treatment) was used as a base material, and the weight after drying was 0.5 g per 100 cm ²
A therapeutic adhesive sheet was prepared in the same manner as in Example 1.

(Drug compatibility/re-release properties) In the obtained therapeutic adhesive sheet, no precipitation or separation of drug particles was observed even after accelerated aging at 60°C for 30 days.

Punch out a circle with a diameter of 60 mm from this sheet at 20°C.
After 30 days at 60°C and 30 days at 60°C, the adhesive sheet alone was mixed with water: methyl alcohol = 95:5.
After soaking in 50ml of the mixed solution and leaving it at 30℃ for 24 hours,
The amount of drug re-released into the extract was determined by liquid chromatography, and the re-release rate was determined.

Sample after 30 days at 20℃ 88.7% Sample after 30 days at 60℃ 74.7% It showed a high level value even after accelerated aging.

(Adhesive force) Measurement was performed in the same manner as in Example 1.

Sample after 30 days at 20°C: 590g/15mm Sample after 30 days at 60°C: 564g/15mm The adhesive had no cohesive failure during the measurement and had an excellent adhesive feel to the touch.

Comparative Example 3 For comparison with Example 3, the following monomer composition: lauroyl methacrylate 149.4 g (0.588 mol) 2-ethylhexyl acrylate
75.8 g (0.412 mol) of ethyl acetate and 56 g of ethyl acetate were polymerized using the same catalyst, method, and conditions as in Example 3 to obtain a solution with a concentration of 25.5% by weight and a polymerization rate of 98.0%.

This was diluted to 22.0% by weight, and a therapeutic adhesive sheet containing diclofenac sodium was prepared in the same manner as in Example 3.

(Drug compatibility) Sample after 30 days at 20℃: Approximately ² to 4 per cm2
Sample precipitated after 30 days at 60°C: Approximately several dozen precipitates per cm ² (Drug re-release properties) The results of testing in the same manner as in Example 3 are shown.

Sample after 30 days at 20℃: 71.8% Sample after 30 days at 60℃: 42.9% (Adhesive strength) Sample after 30 days at 20℃: 537g/15mm Sample after 30 days at 60℃: 388g/15mm Example 4 Diacetone acrylamide 33.8g (0.20 mol) Lauroyl methacrylate 45.7g (0.18 mol) Butyl acrylate 79.4g (0.62 mol) Ethyl acetate 40.g The above solution was heated at 65°C in an atmosphere purged with nitrogen gas.
Dissolve 0.5 g of azobisisobutyronitrile in 100 ml of ethyl acetate and add it in 10 portions.
Polymerization was performed for 30 hours, concentration 26.6% by weight, polymerization rate 99.4
% solution was obtained.

The above solution was diluted to 23.0% by weight, and the solution 100%
A solution of 230 mg of Brednisolone (anti-inflammatory steroid hormone) per g dissolved in a small amount of ethyl alcohol was mixed. From this solution, Example 1
Using the same base material, the amount of adhesive after drying is 100
A therapeutic adhesive sheet was prepared by applying the adhesive at a concentration of 0.45 g per cm ² .

(Drug re-release properties) The therapeutic adhesive sheet was punched into a circle with a diameter of 60 mm, and samples were obtained under three conditions: 30 days at 20°C, 30 days at 60°C, and 30 days at 60°C in sealed packaging with aluminum foil. . Next, in the same manner as in Example 1, using a mixture of water: ethyl alcohol = 95:5, after standing at 30 ° C. for 24 hours, the amount of drug re-released into the extract was measured by liquid chromatography. The re-release rate was determined.

20℃, 30 days later: 95.4% 60℃, 30 days later: 90.6% Aluminum sealed 60℃, 30 days later: 81.5%, maintaining a high level of re-release performance even after particularly severe conditions. For an unstable drug such as prednisolone, this value indicates that the adhesive does not have a negative effect on the drug.

(Appearance/Adhesive Strength) The adhesive layer exhibited strong stickiness and elasticity in terms of adhesive feel to the touch, and no stringy phenomenon occurred.

The adhesive strength measured in the same manner as in Example 1 was as follows.

Sample after 30 days at 20°C: 525g/15mm Sample after 30 days at 60°C: 482g/15mm No abnormality such as stringiness of the adhesive was observed during measurement.

Comparative Example 4 In order to compare with Example 4, the following monomer composition solution lauroyl methacrylate 57.1g (0.225 mol) butyl acrylate 99.3g (0.775 mol) ethyl acetate 40.g was used using the same catalyst and method as in Example 4. Polymerization was carried out under certain conditions to obtain a solution with a concentration of 25.8% by weight and a polymerization rate of 98.1%.

(Drug re-releasing property) Samples were sampled in the same manner as in Example 4, and the results were as follows.

Sample after 30 days at 20℃: 89.2% Sample after 30 days at 60℃: 59.3% Sample after 30 days at 60℃ after sealed aluminum foil packaging:
39.0% (Appearance/adhesive strength) Regarding the adhesive feel to the touch, there were no major defects except for a slight stringiness, but in the adhesive strength measurement, slight cohesive failure occurred on the sample plate in the latter half.

Adhesive strength after 30 days at 20°C: 430 to 840 g/15 mm The variation in these values indicates that the adhesive is not peeling in a stable manner.

Example 5 Diacetone acrylamide 74.4g (0.44mol) 2-ethylhexyl acrylate
103.0g (0.56 mol) Ethyl acetate 76.g The above was stirred at 65°C in an atmosphere replaced with nitrogen gas, and 1.2g of lauroyl peroxide was added to 100% of ethyl acetate.
ml of solution and add it in 12 times,
Polymerization was carried out over 38 hours to obtain a solution with a concentration of 24.2% by weight and a polymerization rate of 98.7%.

(Medical preparation/Preparation of adhesive sheet) Dilute the above solution to 21.0% by weight, and
Per gram, 0.6 g of pentaerythritol tetranitrate (an angina drug) was dissolved in ethyl acetate and mixed.

This solution was used for treatment in the same manner as in Example 1, using a base material (plasticizer-free, soft polyvinyl chloride film: thickness 90 μm) so that the weight after drying was 0.4 g per 100 cm ² . An adhesive sheet was created.

(Appearance/adhesive properties) Adhesive feel to the touch was appropriate, and there was no stringiness of the drug or adhesive residue. The adhesive strength was measured in the same manner as in Example 1 and found to be 481 g/15 mm.

(Drug release properties) A circular sample with a diameter of 60 mm was punched out, sealed and packaged with aluminum foil, opened after 30 days at 20°C, and immersed in a mixture of water: ethyl alcohol = 95:5 in the same manner as in Example 1. After 24 hours at 30℃, the amount of drug re-released into the solvent was measured and the re-release rate was determined.
It was 79.2%.

Comparative Example 5 In order to compare with Example 5, the following monomer composition solution 2-ethylhexyl acrylate 184 (1.0 mol) ethyl acetate 79.g was polymerized using the same catalyst, conditions, and method as in Example 5, and the concentration A polymer solution with a polymerization rate of 22.6% by weight and a polymerization rate of 95.4% was obtained.

From this, a drug-containing adhesive sheet was created using the same method as in Example 5.

(Appearance/adhesive strength) In terms of adhesive feel to the touch, stringing of the adhesive and cohesive failure phenomena were observed. In addition, when the adhesive strength was measured in the same manner as in Example 1, the adhesive strength was 1000% due to the cohesive failure phenomenon.
The value was greater than g/15mm, and a normal value could not be obtained.

[Brief explanation of drawings]

FIG. 1 is a triangular coordinate diagram showing the compositional regions of each component in the therapeutic adhesive tape or sheet of the present invention.

Claims (1)

[Claims] 1. A therapeutic adhesive tape or sheet in which a base material is provided with a pressure-sensitive adhesive layer containing a drug, in which the pressure-sensitive adhesive has a copolymerization content of 5 to 45 mol% of diacetone acrylamide and methacrylic acid. Consists of a copolymer in which the copolymerization amount of alkyl ester is 0 to 60 mol% and the copolymerization amount of acrylic acid alkyl ester is 35 to 85 mol%, based on the total number of moles of diacetone acrylamide and methacrylic acid alkyl ester. The molar ratio of the acrylic acid alkyl ester is within the range of 65:35 to 15:85, the carbon number of the alkyl group of the methacrylic acid alkyl ester is 1 to 12, and the carbon number of the alkyl group of the acrylic acid alkyl ester is A therapeutic adhesive tape or sheet, characterized in that the number is 4 to 12.